1
|
Meinert H, Oehlschläger F, Cziegler C, Rockstroh J, Marzuoli I, Bisagni S, Lalk M, Bayer T, Iding H, Bornscheuer U. Efficient Enzymatic Synthesis of Carbamates in Water Using Promiscuous Esterases/Acyltransferases. Angew Chem Int Ed Engl 2024:e202405152. [PMID: 38739413 DOI: 10.1002/anie.202405152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 05/07/2024] [Accepted: 05/10/2024] [Indexed: 05/14/2024]
Abstract
Biocatalysis provides an attractive approach to facilitate synthetic reactions in aqueous media. Motivated by the discovery of promiscuous aminolysis activity of esterases, we exploited the esterase from Pyrobaculum calidifontis VA1 (PestE) for the synthesis of carbamates from different aliphatic, aromatic, and arylaliphatic amines and a set of carbonates such as dimethyl-, dibenzyl-, or diallyl carbonate. Thus, aniline and benzylamine derivatives, aliphatic and even secondary amines could be efficiently converted into the corresponding benzyloxycarbonyl (Cbz)- or allyloxycarbonyl (Alloc)-protected products in bulk water, with (isolated) yields of up to 99%.
Collapse
Affiliation(s)
- Hannes Meinert
- University of Greifswald, Institute of Biochemistry, GERMANY
| | | | | | - Jan Rockstroh
- University of Greifswald, Dept. of Cellular Biochemistry and Metabolomics, GERMANY
| | - Irene Marzuoli
- F Hoffmann-La Roche Ltd, Process Chemistry & Catalysis, SWITZERLAND
| | - Serena Bisagni
- F Hoffmann-La Roche Ltd, Process Chemistry & Catalysis, SWITZERLAND
| | - Michael Lalk
- University of Greifswald, Dept. of Cellular Biochemistry and Metabolomics, GERMANY
| | - Thomas Bayer
- University of Greifswald, Institute of Biochemistry, GERMANY
| | - Hans Iding
- F Hoffmann-La Roche Ltd, Process Chemistry & Catalysis, SWITZERLAND
| | - Uwe Bornscheuer
- University of Greifswald: Universitat Greifswald, Dept. of Biotechnology & Enzyme Catalysis, Felix-Hausdorff-Str. 4, 17487, Greifswald, GERMANY
| |
Collapse
|
2
|
Honda Malca S, Stockinger P, Duss N, Milbredt D, Iding H, Buller R. Excelzyme: A Swiss University-Industry Collaboration for Accelerated Biocatalyst Development. Chimia (Aarau) 2024; 78:108-117. [PMID: 38547011 DOI: 10.2533/chimia.2024.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 01/25/2024] [Indexed: 04/02/2024] Open
Abstract
Excelzyme, an enzyme engineering platform located at the Zurich University of Applied Sciences, is dedicated to accelerating the development of tailored biocatalysts for large-scale industrial applications. Leveraging automation and advanced computational techniques, including machine learning, efficient biocatalysts can be generated in short timeframes. Toward this goal, Excelzyme systematically selects suitable protein scaffolds as the foundation for constructing complex enzyme libraries, thereby enhancing sequence and structural biocatalyst diversity. Here, we describe applied workflows and technologies as well as an industrial case study that exemplifies the successful application of the workflow.
Collapse
Affiliation(s)
- Sumire Honda Malca
- Competence Center for Biocatalysis, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, CH-8820 Wädenswil, Switzerland.
| | - Peter Stockinger
- Competence Center for Biocatalysis, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, CH-8820 Wädenswil, Switzerland.
| | - Nadine Duss
- Competence Center for Biocatalysis, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, CH-8820 Wädenswil, Switzerland.
| | - Daniela Milbredt
- Competence Center for Biocatalysis, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, CH-8820 Wädenswil, Switzerland.
| | - Hans Iding
- Process Chemistry & Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland.
| | - Rebecca Buller
- Competence Center for Biocatalysis, Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, CH-8820 Wädenswil, Switzerland.
| |
Collapse
|
3
|
Honda Malca S, Duss N, Meierhofer J, Patsch D, Niklaus M, Reiter S, Hanlon SP, Wetzl D, Kuhn B, Iding H, Buller R. Effective engineering of a ketoreductase for the biocatalytic synthesis of an ipatasertib precursor. Commun Chem 2024; 7:46. [PMID: 38418529 PMCID: PMC10902378 DOI: 10.1038/s42004-024-01130-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Accepted: 02/15/2024] [Indexed: 03/01/2024] Open
Abstract
Semi-rational enzyme engineering is a powerful method to develop industrial biocatalysts. Profiting from advances in molecular biology and bioinformatics, semi-rational approaches can effectively accelerate enzyme engineering campaigns. Here, we present the optimization of a ketoreductase from Sporidiobolus salmonicolor for the chemo-enzymatic synthesis of ipatasertib, a potent protein kinase B inhibitor. Harnessing the power of mutational scanning and structure-guided rational design, we created a 10-amino acid substituted variant exhibiting a 64-fold higher apparent kcat and improved robustness under process conditions compared to the wild-type enzyme. In addition, the benefit of algorithm-aided enzyme engineering was studied to derive correlations in protein sequence-function data, and it was found that the applied Gaussian processes allowed us to reduce enzyme library size. The final scalable and high performing biocatalytic process yielded the alcohol intermediate with ≥ 98% conversion and a diastereomeric excess of 99.7% (R,R-trans) from 100 g L-1 ketone after 30 h. Modelling and kinetic studies shed light on the mechanistic factors governing the improved reaction outcome, with mutations T134V, A238K, M242W and Q245S exerting the most beneficial effect on reduction activity towards the target ketone.
Collapse
Affiliation(s)
- Sumire Honda Malca
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Nadine Duss
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Jasmin Meierhofer
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
- Analytical Research and Development, MSD Werthenstein BioPharma GmbH, Industrie Nord 1, 6105 Schachen, Switzerland
| | - David Patsch
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Michael Niklaus
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
| | - Stefanie Reiter
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland
- Manufacturing Science and Technology, Fisher Clinical Services GmbH, Biotech Innovation Park, 2543 Lengnau, Switzerland
| | - Steven Paul Hanlon
- Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Dennis Wetzl
- Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
- Nonclinical Drug Development, Boehringer Ingelheim International GmbH, Birkendorfer Strasse 65, 88397 Biberach an der Riss, Germany
| | - Bernd Kuhn
- Pharmaceutical Research and Early Development, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Hans Iding
- Process Chemistry and Catalysis, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - Rebecca Buller
- Institute of Chemistry and Biotechnology, Zurich University of Applied Sciences, Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.
| |
Collapse
|
4
|
Molinaro C, Kelly S, Tang A, Iding H, Stocker P, Linghu X, Gosselin F. Asymmetric Synthesis of N-Alkyl Amino Acids through a Biocatalytic Dynamic Kinetic Resolution of PEGylated N-Alkyl Amino Esters. Org Lett 2023; 25:8927-8931. [PMID: 38051775 DOI: 10.1021/acs.orglett.3c03784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2023]
Abstract
The first examples of a practical procedure for a lipase-catalyzed dynamic kinetic resolution of PEGylated N-alkyl amino esters is reported. This method allows for the preparation of a broad range of aromatic and aliphatic enantiomerically enriched N-alkyl unnatural amino acids in up to 98% yield and 99% ee. We have found that PEGylated esters have a significant solubility advantage and improved reactivity over traditional hydrophobic lipase substrates, thereby allowing for efficient and scalable dynamic kinetic resolution (DKR) under aqueous conditions.
Collapse
Affiliation(s)
- Carmela Molinaro
- Department of Small Molecule Process Chemistry, Genentech USA, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Sean Kelly
- Department of Small Molecule Process Chemistry, Genentech USA, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Allison Tang
- Department of Small Molecule Process Chemistry, Genentech USA, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Hans Iding
- Department of Process Chemistry & Catalysis, Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Patrik Stocker
- Department of Process Chemistry & Catalysis, Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Xin Linghu
- Department of Small Molecule Process Chemistry, Genentech USA, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| | - Francis Gosselin
- Department of Small Molecule Process Chemistry, Genentech USA, Inc. 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
5
|
St-Jean F, Angelaud R, Bachmann S, Carrera DE, Remarchuk T, Piechowicz KA, Niedermann K, Iding H, Meier R, Hou H, Sirois LE, Xu J, Olbrich M, Rege P, Guillemot-Plass M, Gosselin F. Stereoselective Synthesis of the IDO Inhibitor Navoximod. J Org Chem 2022; 87:4955-4960. [PMID: 35317556 DOI: 10.1021/acs.joc.1c02994] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
A highly efficient asymmetric synthesis of the IDO inhibitor navoximod, featuring the stereoselective installation of two relative and two absolute stereocenters from an advanced racemic intermediate, is described. The stereocenters were set via a crystallization-induced dynamic resolution along with two selective ketone reductions: one via a biocatalytic ketoreductase transformation and one via substrate-controlled hydride delivery from LiAlH(Ot-Bu)3. Following this strategy, navoximod was synthesized in 10 steps from 2-fluorobenzaldehyde and isolated in 23% overall yield with 99.7% ee and high purity.
Collapse
Affiliation(s)
- Frédéric St-Jean
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Rémy Angelaud
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Stephan Bachmann
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Diane E Carrera
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Travis Remarchuk
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Katarzyna A Piechowicz
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Katrin Niedermann
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Hans Iding
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Roland Meier
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Haiyun Hou
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Lauren E Sirois
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Jie Xu
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Martin Olbrich
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Pankaj Rege
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Maud Guillemot-Plass
- Synthetic Molecules Technical Development, F. Hoffmann-La Roche Ltd., Grenzacherstraße 124, 4070 Basel, Switzerland
| | - Francis Gosselin
- Department of Small Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
6
|
Contente ML, Marzuoli I, Iding H, Wetzl D, Puentener K, Hanlon SP, Paradisi F. Screening methods for enzyme-mediated alcohol oxidation. Sci Rep 2022; 12:3019. [PMID: 35194101 PMCID: PMC8864024 DOI: 10.1038/s41598-022-07008-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Accepted: 02/10/2022] [Indexed: 11/22/2022] Open
Abstract
Alcohol oxidation for the generation of carbonyl groups, is an essential reaction for the preparation of fine chemicals. Although a number of chemical procedures have been reported, biocatalysis is a promising alternative for more sustainable and selective processes. To speed up the discovery of novel (bio)catalysts for industrial applications, efficient screening approaches need to be established. Here, we report on an enzyme-mediated alcohol oxidation screening platform to rapidly detect the activities and selectivities of three classes of biocatalysts; ketoreductases (KREDs), alcohol oxidases (AlcOXs) and laccase-mediator systems (LMSs) with diverse substrates.
Collapse
Affiliation(s)
- Martina L Contente
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freistrasse 3, 3012, Bern, Switzerland.,Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Via Celoria 2, 20133, Milan, Italy
| | - Irene Marzuoli
- F. Hoffmann-La Roche Ltd, Process Chemistry and Catalysis (PCC), Grenzacherstrasse, 4070, Basel, Switzerland
| | - Hans Iding
- F. Hoffmann-La Roche Ltd, Process Chemistry and Catalysis (PCC), Grenzacherstrasse, 4070, Basel, Switzerland
| | - Dennis Wetzl
- F. Hoffmann-La Roche Ltd, Process Chemistry and Catalysis (PCC), Grenzacherstrasse, 4070, Basel, Switzerland
| | - Kurt Puentener
- F. Hoffmann-La Roche Ltd, Process Chemistry and Catalysis (PCC), Grenzacherstrasse, 4070, Basel, Switzerland
| | - Steven P Hanlon
- F. Hoffmann-La Roche Ltd, Process Chemistry and Catalysis (PCC), Grenzacherstrasse, 4070, Basel, Switzerland.
| | - Francesca Paradisi
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freistrasse 3, 3012, Bern, Switzerland.
| |
Collapse
|
7
|
Bachmann S, Iding H, Lautz C, Thomé-Pfeiffer I, Maierhofer C, Mondière R, Schmidt P, Strasser C, Bär T, Aebi A, Schuster A. Development of the Commercial Manufacturing Process for Ipatasertib. Chimia (Aarau) 2021; 75:605-613. [PMID: 34523401 DOI: 10.2533/chimia.2021.605] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Ipatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.
Collapse
Affiliation(s)
- Stephan Bachmann
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Hans Iding
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Christian Lautz
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Isabelle Thomé-Pfeiffer
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Caroline Maierhofer
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Régis Mondière
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Philipp Schmidt
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Christoph Strasser
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Thomas Bär
- Dottikon Exclusive Synthesis AG, Hembrunnstrasse 17, CH-5605 Dottikon, Switzerland
| | - André Aebi
- Dottikon Exclusive Synthesis AG, Hembrunnstrasse 17, CH-5605 Dottikon, Switzerland
| | - Andreas Schuster
- Department of Process Chemistry & Catalysis, Pharma Synthetic Molecules Technical Development, F. Hoffmann-La Roche AG, Grenzacherstrasse 124, CH-4070 Basel, Switzerland;,
| |
Collapse
|
8
|
Voss M, Küng R, Hayashi T, Jonczyk M, Niklaus M, Iding H, Wetzl D, Buller R. Cover Feature: Multi‐faceted Set‐up of a Diverse Ketoreductase Library Enables the Synthesis of Pharmaceutically‐relevant Secondary Alcohols (6/2021). ChemCatChem 2021. [DOI: 10.1002/cctc.202100215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Moritz Voss
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Robin Küng
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
- Present address: Fisher Clinical Services Thermo Fisher Scientific Steinbühlweg 69 4123 Allschwil Switzerland
| | - Takahiro Hayashi
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
- Present address: Science & Innovation Center Mitsubishi Chemical Corporation 1000 Kamoshidacho Aoba ward, Yokohama Kanagawa 227-8502 Japan
| | - Magdalena Jonczyk
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Michael Niklaus
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Hans Iding
- Process Chemistry & Catalysis F. Hoffmann-La Roche Ltd
| | - Dennis Wetzl
- Process Chemistry & Catalysis F. Hoffmann-La Roche Ltd
| | - Rebecca Buller
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| |
Collapse
|
9
|
Voss M, Küng R, Hayashi T, Jonczyk M, Niklaus M, Iding H, Wetzl D, Buller R. Multi‐faceted Set‐up of a Diverse Ketoreductase Library Enables the Synthesis of Pharmaceutically‐relevant Secondary Alcohols. ChemCatChem 2021. [DOI: 10.1002/cctc.202001871] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Moritz Voss
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Robin Küng
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
- Present address: Fisher Clinical Services Thermo Fisher Scientific Steinbühlweg 69 4123 Allschwil Switzerland
| | - Takahiro Hayashi
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
- Present address: Science & Innovation Center Mitsubishi Chemical Corporation 1000 Kamoshidacho Aoba ward, Yokohama Kanagawa 227-8502 Japan
| | - Magdalena Jonczyk
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Michael Niklaus
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| | - Hans Iding
- Process Chemistry & Catalysis F. Hoffmann-La Roche Ltd. CH-4070 Basel Switzerland
| | - Dennis Wetzl
- Process Chemistry & Catalysis F. Hoffmann-La Roche Ltd. CH-4070 Basel Switzerland
| | - Rebecca Buller
- Competence Center for Biocatalysis Institute for Chemistry and Biotechnology Zurich University of Applied Sciences Einsiedlerstrasse 31 8820 Wädenswil Switzerland
| |
Collapse
|
10
|
Eger E, Schrittwieser JH, Wetzl D, Iding H, Kuhn B, Kroutil W. Asymmetric Biocatalytic Synthesis of 1-Aryltetrahydro-β-carbolines Enabled by "Substrate Walking". Chemistry 2020; 26:16281-16285. [PMID: 33017078 PMCID: PMC7756766 DOI: 10.1002/chem.202004449] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2020] [Indexed: 12/19/2022]
Abstract
Stereoselective catalysts for the Pictet-Spengler reaction of tryptamines and aldehydes may allow a simple and fast approach to chiral 1-substituted tetrahydro-β-carbolines. Although biocatalysts have previously been employed for the Pictet-Spengler reaction, not a single one accepts benzaldehyde and its substituted derivatives. To address this challenge, a combination of substrate walking and transfer of beneficial mutations between different wild-type backbones was used to develop a strictosidine synthase from Rauvolfia serpentina (RsSTR) into a suitable enzyme for the asymmetric Pictet-Spengler condensation of tryptamine and benzaldehyde derivatives. The double variant RsSTR V176L/V208A accepted various ortho-, meta- and para-substituted benzaldehydes and produced the corresponding chiral 1-aryl-tetrahydro-β-carbolines with up to 99 % enantiomeric excess.
Collapse
Affiliation(s)
- Elisabeth Eger
- Institute of Chemistry, Biocatalytic SynthesisUniversity of Graz, NAWI Graz, BioTechMed GrazHeinrichstrasse 28/II8010GrazAustria
| | - Joerg H. Schrittwieser
- Institute of Chemistry, Biocatalytic SynthesisUniversity of Graz, NAWI Graz, BioTechMed GrazHeinrichstrasse 28/II8010GrazAustria
| | - Dennis Wetzl
- Process Chemistry & CatalysisF. Hoffmann-La Roche Ltd.Grenzacherstrasse 1244070BaselSwitzerland
| | - Hans Iding
- Process Chemistry & CatalysisF. Hoffmann-La Roche Ltd.Grenzacherstrasse 1244070BaselSwitzerland
| | - Bernd Kuhn
- Pharma Research & Early DevelopmentF. Hoffmann-La Roche Ltd.Grenzacherstrasse 1244070BaselSwitzerland
| | - Wolfgang Kroutil
- Institute of Chemistry, Biocatalytic SynthesisUniversity of Graz, NAWI Graz, BioTechMed GrazHeinrichstrasse 28/II8010GrazAustria
- Field of Excellence BioHealth—University of Graz8010GrazAustria
| |
Collapse
|
11
|
Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, Woltering TJ, Muri D, Iding H, Bürkler M, Binder M, Bartelmus C, Knuesel I, Pacher P, Herde AM, Spinelli F, Ahmed H, Atz K, Keller C, Weber M, Schibli R, Mu L, Grether U, Ametamey SM. Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. J Med Chem 2020; 63:10287-10306. [PMID: 32787079 DOI: 10.1021/acs.jmedchem.0c00778] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory processes, a suitable CB2-targeted probe is currently lacking in clinical routine. In this work, we synthesized 15 fluorinated pyridine derivatives and tested their binding affinities toward CB2 and CB1. With a sub-nanomolar affinity (Ki for CB2) of 0.8 nM and a remarkable selectivity factor of >12,000 over CB1, RoSMA-18-d6 exhibited outstanding in vitro performance characteristics and was radiofluorinated with an average radiochemical yield of 10.6 ± 3.8% (n = 16) and molar activities ranging from 52 to 65 GBq/μmol (radiochemical purity > 99%). [18F]RoSMA-18-d6 showed exceptional CB2 attributes as demonstrated by in vitro autoradiography, ex vivo biodistribution, and positron emission tomography (PET). Further, [18F]RoSMA-18-d6 was used to detect CB2 upregulation on postmortem human ALS spinal cord tissues. Overall, these results suggest that [18F]RoSMA-18-d6 is a promising CB2 PET radioligand for clinical translation.
Collapse
Affiliation(s)
- Ahmed Haider
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Luca Gobbi
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Julian Kretz
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Christoph Ullmer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Andreas Brink
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Michael Honer
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Thomas J Woltering
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Dieter Muri
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Hans Iding
- Pharma Technical Development, F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland
| | - Markus Bürkler
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Martin Binder
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Christian Bartelmus
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Irene Knuesel
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Pal Pacher
- Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute of Health/NIAAA, 5625 Fishers Lane, Rockville, 20852 Maryland, United States
| | - Adrienne Müller Herde
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Francesco Spinelli
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Hazem Ahmed
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Kenneth Atz
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Claudia Keller
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| | - Markus Weber
- Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, 9007 St. Gallen, Switzerland
| | - Roger Schibli
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland.,Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Linjing Mu
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland.,Department of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
| | - Uwe Grether
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, 4070 Basel, Switzerland
| | - Simon M Ametamey
- Institute of Pharmaceutical Sciences, ETH Zurich, Vladimir-Prelog-Weg 4, 8093 Zurich, Switzerland
| |
Collapse
|
12
|
Dawood AWH, Weiß MS, Schulz C, Pavlidis IV, Iding H, de Souza ROMA, Bornscheuer UT. Isopropylamine as Amine Donor in Transaminase-Catalyzed Reactions: Better Acceptance through Reaction and Enzyme Engineering. ChemCatChem 2018. [DOI: 10.1002/cctc.201800936 and 21=21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Ayad W. H. Dawood
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Martin S. Weiß
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Christian Schulz
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Ioannis V. Pavlidis
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
- Department of Chemistry; University of Crete; Voutes University Campus Heraklion 70013 Greece
| | - Hans Iding
- Process Chemistry and Catalysis, Biocatalysis; F. Hoffmann-La Roche Ltd.; Grenzacher Strasse 124 Basel 4070 Switzerland
| | - Rodrigo O. M. A. de Souza
- Biocatalysis and Organic Synthesis Group, Institute of Chemistry; Federal University of Rio de Janeiro; Brazil
| | - Uwe T. Bornscheuer
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| |
Collapse
|
13
|
Dawood AWH, Weiß MS, Schulz C, Pavlidis IV, Iding H, de Souza ROMA, Bornscheuer UT. Isopropylamine as Amine Donor in Transaminase-Catalyzed Reactions: Better Acceptance through Reaction and Enzyme Engineering. ChemCatChem 2018. [DOI: 10.1002/cctc.201800936 and 67=89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Ayad W. H. Dawood
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Martin S. Weiß
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Christian Schulz
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Ioannis V. Pavlidis
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
- Department of Chemistry; University of Crete; Voutes University Campus Heraklion 70013 Greece
| | - Hans Iding
- Process Chemistry and Catalysis, Biocatalysis; F. Hoffmann-La Roche Ltd.; Grenzacher Strasse 124 Basel 4070 Switzerland
| | - Rodrigo O. M. A. de Souza
- Biocatalysis and Organic Synthesis Group, Institute of Chemistry; Federal University of Rio de Janeiro; Brazil
| | - Uwe T. Bornscheuer
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| |
Collapse
|
14
|
Dawood AWH, Weiß MS, Schulz C, Pavlidis IV, Iding H, de Souza ROMA, Bornscheuer UT. Isopropylamine as Amine Donor in Transaminase-Catalyzed Reactions: Better Acceptance through Reaction and Enzyme Engineering. ChemCatChem 2018. [DOI: 10.1002/cctc.201800936] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Ayad W. H. Dawood
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Martin S. Weiß
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Christian Schulz
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| | - Ioannis V. Pavlidis
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
- Department of Chemistry; University of Crete; Voutes University Campus Heraklion 70013 Greece
| | - Hans Iding
- Process Chemistry and Catalysis, Biocatalysis; F. Hoffmann-La Roche Ltd.; Grenzacher Strasse 124 Basel 4070 Switzerland
| | - Rodrigo O. M. A. de Souza
- Biocatalysis and Organic Synthesis Group, Institute of Chemistry; Federal University of Rio de Janeiro; Brazil
| | - Uwe T. Bornscheuer
- Department of Biotechnology & Enzyme Catalysis, Institute of Biochemistry; Greifswald University; Felix-Hausdorff-Str. 4 Greifswald 17487 Germany
| |
Collapse
|
15
|
Weiß MS, Pavlidis IV, Spurr P, Hanlon SP, Wirz B, Iding H, Bornscheuer UT. Protein-engineering of an amine transaminase for the stereoselective synthesis of a pharmaceutically relevant bicyclic amine. Org Biomol Chem 2018; 14:10249-10254. [PMID: 27739550 DOI: 10.1039/c6ob02139e] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Application of amine transaminases (ATAs) for stereoselective amination of prochiral ketones represents an environmentally benign and economically attractive alternative to transition metal catalyzed asymmetric synthesis. However, the restrictive substrate scope has limited the conversion typically to non-sterically demanding scaffolds. Recently, we reported on the identification and design of fold class I ATAs that effect a highly selective asymmetric synthesis of a set of chiral aromatic bulky amines from the corresponding ketone precursors in high yield. However, for the specific amine synthetic approach extension targeted here, the selective formation of an exo- vs. endo-isomer, these biocatalysts required additional refinement. The chosen substrate (exo-3-amino-8-aza-bicyclo[3.2.1]oct-8-yl-phenyl-methanone), apart from its pharmacological relevance, is a demanding target for ATAs as the bridged bicyclic ring provides substantial steric challenges. Protein engineering combining rational design and directed evolution enabled the identification of an ATA variant which catalyzes the specific synthesis of the target exo-amine with >99.5% selectivity.
Collapse
Affiliation(s)
- Martin S Weiß
- Dept of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.
| | - Ioannis V Pavlidis
- Dept of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany. and Group of Biotechnology, Dept of Biochemistry, University of Kassel, Heinrich-Plett-Str. 40, D-34132 Kassel, Germany
| | - Paul Spurr
- Process Research and Development, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Str.124, 4070 Basel, Switzerland.
| | - Steven P Hanlon
- Process Research and Development, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Str.124, 4070 Basel, Switzerland.
| | - Beat Wirz
- Process Research and Development, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Str.124, 4070 Basel, Switzerland.
| | - Hans Iding
- Process Research and Development, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Str.124, 4070 Basel, Switzerland.
| | - Uwe T Bornscheuer
- Dept of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.
| |
Collapse
|
16
|
Rudroff F, Mihovilovic MD, Gröger H, Snajdrova R, Iding H, Bornscheuer UT. Opportunities and challenges for combining chemo- and biocatalysis. Nat Catal 2018. [DOI: 10.1038/s41929-017-0010-4] [Citation(s) in RCA: 371] [Impact Index Per Article: 61.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
17
|
Han C, Savage S, Al-Sayah M, Yajima H, Remarchuk T, Reents R, Wirz B, Iding H, Bachmann S, Fantasia SM, Scalone M, Hell A, Hidber P, Gosselin F. Asymmetric Synthesis of Akt Kinase Inhibitor Ipatasertib. Org Lett 2017; 19:4806-4809. [PMID: 28858516 DOI: 10.1021/acs.orglett.7b02228] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A highly efficient asymmetric synthesis of the Akt kinase inhibitor ipatasertib (1) is reported. The bicyclic pyrimidine 2 starting material was prepared via a nitrilase biocatalytic resolution, halogen-metal exchange/anionic cyclization, and a highly diastereoselective biocatalytic ketone reduction as key steps. The route also features a halide activated, Ru-catalyzed asymmetric hydrogenation of a vinylogous carbamic acid to produce α-aryl-β-amino acid 3 in high yield and enantioselectivity. The API was assembled in a convergent manner through a late-stage amidation/deprotection/monohydrochloride salt formation sequence.
Collapse
Affiliation(s)
| | | | | | | | | | - Reinhard Reents
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Beat Wirz
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Hans Iding
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Stephan Bachmann
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Serena M Fantasia
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Michelangelo Scalone
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - André Hell
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | - Pirmin Hidber
- Department of Pharma Technical Development Small Molecules, F. Hoffmann-La Roche AG , Grenzacherstrasse 124, CH-4070 Basel, Switzerland
| | | |
Collapse
|
18
|
Roth S, Präg A, Wechsler C, Marolt M, Ferlaino S, Lüdeke S, Sandon N, Wetzl D, Iding H, Wirz B, Müller M. Extended Catalytic Scope of a Well-Known Enzyme: Asymmetric Reduction of Iminium Substrates by Glucose Dehydrogenase. Chembiochem 2017; 18:1703-1706. [PMID: 28722796 DOI: 10.1002/cbic.201700261] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Indexed: 11/10/2022]
Abstract
NADP(H)-dependent imine reductases (IREDs) are of interest in biocatalytic research due to their ability to generate chiral amines from imine/iminium substrates. In reaction protocols involving IREDs, glucose dehydrogenase (GDH) is generally used to regenerate the expensive cofactor NADPH by oxidation of d-glucose to gluconolactone. We have characterized different IREDs with regard to reduction of a set of bicyclic iminium compounds and have utilized 1 H NMR and GC analyses to determine degree of substrate conversion and product enantiomeric excess (ee). All IREDs reduced the tested iminium compounds to the corresponding chiral amines. Blank experiments without IREDs also showed substrate conversion, however, thus suggesting an iminium reductase activity of GDH. This unexpected observation was confirmed by additional experiments with GDHs of different origin. The reduction of C=N bonds with good levels of conversion (>50 %) and excellent enantioselectivity (up to >99 % ee) by GDH represents a promiscuous catalytic activity of this enzyme.
Collapse
Affiliation(s)
- Sebastian Roth
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| | - Andreas Präg
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| | - Cindy Wechsler
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| | - Marija Marolt
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| | - Sascha Ferlaino
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| | - Steffen Lüdeke
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| | - Nicolas Sandon
- Process Chemistry and Catalysis, F. Hoffmann-La Roche, Ltd., 4070, Basel, Switzerland
| | - Dennis Wetzl
- Process Chemistry and Catalysis, F. Hoffmann-La Roche, Ltd., 4070, Basel, Switzerland
| | - Hans Iding
- Process Chemistry and Catalysis, F. Hoffmann-La Roche, Ltd., 4070, Basel, Switzerland
| | - Beat Wirz
- Process Chemistry and Catalysis, F. Hoffmann-La Roche, Ltd., 4070, Basel, Switzerland
| | - Michael Müller
- Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104, Freiburg, Germany
| |
Collapse
|
19
|
Weiß MS, Pavlidis IV, Spurr P, Hanlon SP, Wirz B, Iding H, Bornscheuer UT. Amine Transaminase Engineering for Spatially Bulky Substrate Acceptance. Chembiochem 2017; 18:1022-1026. [PMID: 28334484 DOI: 10.1002/cbic.201700033] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Indexed: 11/09/2022]
Abstract
Amine transaminase (ATA) catalyzing stereoselective amination of prochiral ketones is an attractive alternative to transition metal catalysis. As wild-type ATAs do not accept sterically hindered ketones, efforts to widen the substrate scope to more challenging targets are of general interest. We recently designed ATAs to accept aromatic and thus planar bulky amines, with a sequence-based motif that supports the identification of novel enzymes. However, these variants were not active against 2,2-dimethyl-1-phenyl-propan-1-one, which carries a bulky tert-butyl substituent adjacent to the carbonyl function. Here, we report a solution for this type of substrate. The evolved ATAs perform asymmetric synthesis of the respective R amine with high conversions by using either alanine or isopropylamine as amine donor.
Collapse
Affiliation(s)
- Martin S Weiß
- Department of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Strasse 4, 17489, Greifswald, Germany
| | - Ioannis V Pavlidis
- Department of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Strasse 4, 17489, Greifswald, Germany.,Group of Biotechnology, Department of Biochemistry, University of Kassel, Heinrich-Plett-Strasse 40, 34132, Kassel, Germany
| | - Paul Spurr
- Process Chemistry and Catalysis, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Strasse 124, 4070, Basel, Switzerland
| | - Steven P Hanlon
- Process Chemistry and Catalysis, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Strasse 124, 4070, Basel, Switzerland
| | - Beat Wirz
- Process Chemistry and Catalysis, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Strasse 124, 4070, Basel, Switzerland
| | - Hans Iding
- Process Chemistry and Catalysis, Biocatalysis, F. Hoffmann-La Roche Ltd., Grenzacher Strasse 124, 4070, Basel, Switzerland
| | - Uwe T Bornscheuer
- Department of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Strasse 4, 17489, Greifswald, Germany
| |
Collapse
|
20
|
Linghu X, Wong N, Iding H, Jost V, Zhang H, Koenig SG, Sowell CG, Gosselin F. Development of a Practical Synthesis of ERK Inhibitor GDC-0994. Org Process Res Dev 2017. [DOI: 10.1021/acs.oprd.7b00006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- Xin Linghu
- Small
Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Nicholas Wong
- Small
Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Hans Iding
- Process Research,
F. Hoffmann-La Roche AG, Grenzacherstrasse
124, CH-4070 Basel, Switzerland
| | - Vera Jost
- Process Research,
F. Hoffmann-La Roche AG, Grenzacherstrasse
124, CH-4070 Basel, Switzerland
| | - Haiming Zhang
- Small
Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Stefan G. Koenig
- Small
Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - C. Gregory Sowell
- Small
Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| | - Francis Gosselin
- Small
Molecule Process Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States
| |
Collapse
|
21
|
Gröger H, Zumbrägel N, Wetzl D, Iding H. Asymmetric Biocatalytic Reduction of Cyclic Imines: Design and Application of a Tailor-Made Whole-Cell Catalyst. HETEROCYCLES 2017. [DOI: 10.3987/com-16-s(s)89] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
22
|
Zumbrägel N, Wetzl D, Iding H, Gröger H. Process Development of Imine Reductase-Catalyzed Enantioselective Synthesis of Cyclic Amines. CHEM-ING-TECH 2016. [DOI: 10.1002/cite.201650109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
23
|
Pavlidis IV, Weiß MS, Genz M, Spurr P, Hanlon SP, Wirz B, Iding H, Bornscheuer UT. Identification of (S)-selective transaminases for the asymmetric synthesis of bulky chiral amines. Nat Chem 2016; 8:1076-1082. [PMID: 27768108 DOI: 10.1038/nchem.2578] [Citation(s) in RCA: 160] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 06/16/2016] [Indexed: 11/09/2022]
Abstract
The use of transaminases to access pharmaceutically relevant chiral amines is an attractive alternative to transition-metal-catalysed asymmetric chemical synthesis. However, one major challenge is their limited substrate scope. Here we report the creation of highly active and stereoselective transaminases starting from fold class I. The transaminases were developed by extensive protein engineering followed by optimization of the identified motif. The resulting enzymes exhibited up to 8,900-fold higher activity than the starting scaffold and are highly stereoselective (up to >99.9% enantiomeric excess) in the asymmetric synthesis of a set of chiral amines bearing bulky substituents. These enzymes should therefore be suitable for use in the synthesis of a wide array of potential intermediates for pharmaceuticals. We also show that the motif can be engineered into other protein scaffolds with sequence identities as low as 70%, and as such should have a broad impact in the field of biocatalytic synthesis and enzyme engineering.
Collapse
Affiliation(s)
- Ioannis V Pavlidis
- Department of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany.,Department of Biochemistry, University of Kassel, Heinrich-Plett-Str. 40, D-34132 Kassel, Germany
| | - Martin S Weiß
- Department of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany
| | - Maika Genz
- Department of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany
| | - Paul Spurr
- Process Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland
| | - Steven P Hanlon
- Process Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland
| | - Beat Wirz
- Process Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland
| | - Hans Iding
- Process Research and Development, Biocatalysis, F. Hoffmann-LaRoche Ltd, Grenzacher Str. 124, 4070 Basel, Switzerland
| | - Uwe T Bornscheuer
- Department of Biotechnology, Institute of Biochemistry, University of Greifswald, Felix-Hausdorff-Str. 4, D-17489 Greifswald, Germany
| |
Collapse
|
24
|
Wetzl D, Gand M, Ross A, Müller H, Matzel P, Hanlon SP, Müller M, Wirz B, Höhne M, Iding H. Back Cover: Asymmetric Reductive Amination of Ketones Catalyzed by Imine Reductases (ChemCatChem 12/2016). ChemCatChem 2016. [DOI: 10.1002/cctc.201600684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Dennis Wetzl
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Martin Gand
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Alfred Ross
- Pharmaceutical Research and Early Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Hubertus Müller
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Philipp Matzel
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Steven P. Hanlon
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Michael Müller
- Institute of Pharmaceutical Sciences; Albert-Ludwigs-Universität Freiburg; Albertstrasse 25 79104 Freiburg Germany
| | - Beat Wirz
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Matthias Höhne
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Hans Iding
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| |
Collapse
|
25
|
Wetzl D, Gand M, Ross A, Müller H, Matzel P, Hanlon SP, Müller M, Wirz B, Höhne M, Iding H. Asymmetric Reductive Amination of Ketones Catalyzed by Imine Reductases. ChemCatChem 2016. [DOI: 10.1002/cctc.201600384] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Affiliation(s)
- Dennis Wetzl
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Martin Gand
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Alfred Ross
- Pharmaceutical Research and Early Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Hubertus Müller
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Philipp Matzel
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Steven P. Hanlon
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Michael Müller
- Institute of Pharmaceutical Sciences; Albert-Ludwigs-Universität Freiburg; Albertstrasse 25 79104 Freiburg Germany
| | - Beat Wirz
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| | - Matthias Höhne
- Institute of Biochemistry; Ernst-Moritz-Arndt-Universität Greifswald; Felix-Hausdorff-Str. 4 17487 Greifswald Germany
| | - Hans Iding
- Process Research & Development; F. Hoffmann-La Roche Ltd.; CH-4070 Basel Switzerland
| |
Collapse
|
26
|
Edelmann MR, Hartung T, Trussardi R, Iding H, Galley G, Pflieger P, Norcross RD. Synthesis of enantiomerically pure [14C]-labelled morpholine derivatives for a class of trace amine-associate receptor 1 agonists. J Labelled Comp Radiopharm 2016; 59:635-639. [DOI: 10.1002/jlcr.3403] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Revised: 03/29/2016] [Accepted: 04/04/2016] [Indexed: 11/10/2022]
Affiliation(s)
- Martin R. Edelmann
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| | - Thomas Hartung
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| | - René Trussardi
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| | - Hans Iding
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| | - Guido Galley
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| | - Philippe Pflieger
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| | - Roger D. Norcross
- Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel; F. Hoffmann-La Roche Ltd; Grenzacherstrasse 124 4070 Basel Switzerland
| |
Collapse
|
27
|
Wetzl D, Berrera M, Sandon N, Fishlock D, Ebeling M, Müller M, Hanlon S, Wirz B, Iding H. Inside Back Cover: Expanding the Imine Reductase Toolbox by Exploring the Bacterial Protein-Sequence Space (ChemBioChem 12/2015). Chembiochem 2015. [DOI: 10.1002/cbic.201590035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
28
|
Wetzl D, Berrera M, Sandon N, Fishlock D, Ebeling M, Müller M, Hanlon S, Wirz B, Iding H. Expanding the Imine Reductase Toolbox by Exploring the Bacterial Protein-Sequence Space. Chembiochem 2015; 16:1749-56. [PMID: 26044455 DOI: 10.1002/cbic.201500218] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Indexed: 11/11/2022]
Abstract
Recent investigations on imine reductases (IREDs) have enriched the toolbox of potential catalysts for accessing chiral amines, which are important building blocks for the pharmaceutical industry. Herein, we describe the characterization of 20 new IREDs. A C-terminal domain clustering of the bacterial protein-sequence space was performed to identify the novel IRED candidates. Each of the identified enzymes was characterized against a set of nine cyclic imine model substrates. A refined clustering towards putative active-site residues was performed and was consistent both with our screening and previously reported results. Finally, preparative scale experiments on a 100 mg scale with two purified IREDs, IR_20 from Streptomyces tsukubaensis and IR_23 from Streptomyces vidiochromogenes, were carried out to provide (R)-2-methylpiperidine in 98% ee (71% yield) and (R)-1-methyl-1,2,3,4-tetrahydroisoquinoline in >98% ee (82% yield).
Collapse
Affiliation(s)
- Dennis Wetzl
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Marco Berrera
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland).,Pharmaceutical Research and Early Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Nicolas Sandon
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Dan Fishlock
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Martin Ebeling
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland).,Pharmaceutical Research and Early Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Michael Müller
- Institute of Pharmaceutical Sciences, Albert-Ludwigs-Universität Freiburg, Albertstrasse 25, 79104 Freiburg (Germany)
| | - Steven Hanlon
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Beat Wirz
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland)
| | - Hans Iding
- Process Research and Development, F. Hoffmann-La Roche Ltd. Grenzacherstrasse 124, 4070 Basel (Switzerland).
| |
Collapse
|
29
|
Reß T, Hummel W, Hanlon SP, Iding H, Gröger H. The Organic-Synthetic Potential of Recombinant Ene Reductases: Substrate-Scope Evaluation and Process Optimization. ChemCatChem 2015. [DOI: 10.1002/cctc.201402903] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
30
|
Hilpert H, Mauser H, Humm R, Anselm L, Kuehne H, Hartmann G, Gruener S, Banner DW, Benz J, Gsell B, Kuglstatter A, Stihle M, Thoma R, Sanchez RA, Iding H, Wirz B, Haap W. Identification of Potent and Selective Cathepsin S Inhibitors Containing Different Central Cyclic Scaffolds. J Med Chem 2013; 56:9789-801. [DOI: 10.1021/jm401528k] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
- Hans Hilpert
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Harald Mauser
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Roland Humm
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Lilli Anselm
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Holger Kuehne
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Guido Hartmann
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Sabine Gruener
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - David W. Banner
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Joerg Benz
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Bernard Gsell
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Andreas Kuglstatter
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Martine Stihle
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Ralf Thoma
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Rubén Alvarez Sanchez
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Hans Iding
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Beat Wirz
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| | - Wolfgang Haap
- Discovery Chemistry, ‡Cardiovascular and
Metabolic Diseases, §Discovery Technologies, ∥Drug Metabolism
and Pharmacokinetics, ⊥Process Research and Synthesis, Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, Basel CH-4070, Switzerland
| |
Collapse
|
31
|
Zhang P, Iding H, Cedilote M, Brunner S, Williamson T, Cleary TP. A practical synthesis of (2R)-3,5-di-O-benzoyl-2-fluoro-2-C-methyl-d-ribono-γ-lactone. ACTA ACUST UNITED AC 2009. [DOI: 10.1016/j.tetasy.2009.02.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
32
|
Zutter U, Iding H, Spurr P, Wirz B. New, Efficient Synthesis of Oseltamivir Phosphate (Tamiflu) via Enzymatic Desymmetrization of a meso-1,3-Cyclohexanedicarboxylic Acid Diester. J Org Chem 2008; 73:4895-902. [DOI: 10.1021/jo800264d] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ulrich Zutter
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Technical Sciences, Synthesis & Process Research and Biocatalysis, CH-4070 Basel, Switzerland
| | - Hans Iding
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Technical Sciences, Synthesis & Process Research and Biocatalysis, CH-4070 Basel, Switzerland
| | - Paul Spurr
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Technical Sciences, Synthesis & Process Research and Biocatalysis, CH-4070 Basel, Switzerland
| | - Beat Wirz
- F. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Technical Sciences, Synthesis & Process Research and Biocatalysis, CH-4070 Basel, Switzerland
| |
Collapse
|
33
|
Dias Lucas S, Iding H, Alker A, Peter Wessel H, Pilar Rauter A. Oxetane δ‐Amino Acids: Chemoenzymatic Synthesis of 2,4‐Anhydro‐5‐N‐(t‐butoxycarbonyl)amino‐D‐lyxonic Acid. J Carbohydr Chem 2006. [DOI: 10.1080/07328300600732485] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Susana Dias Lucas
- a F. Hoffmann‐La Roche Ltd., Pharmaceutical Research , Basel, Switzerland
| | - Hans Iding
- a F. Hoffmann‐La Roche Ltd., Pharmaceutical Research , Basel, Switzerland
| | - André Alker
- a F. Hoffmann‐La Roche Ltd., Pharmaceutical Research , Basel, Switzerland
| | - Hans Peter Wessel
- a F. Hoffmann‐La Roche Ltd., Pharmaceutical Research , Basel, Switzerland
| | - Amélia Pilar Rauter
- b Departamento de Química e Bioquímica , Faculdade de Ciências da Universidade de Lisboa , Campo Grande, Lisboa, Portugal
| |
Collapse
|
34
|
Siegert P, McLeish MJ, Baumann M, Iding H, Kneen MM, Kenyon GL, Pohl M. Exchanging the substrate specificities of pyruvate decarboxylase from Zymomonas mobilis and benzoylformate decarboxylase from Pseudomonas putida. Protein Eng Des Sel 2005; 18:345-57. [PMID: 15930043 DOI: 10.1093/protein/gzi035] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Pyruvate decarboxylase from Zymomonas mobilis (PDC) and benzoylformate decarboxylase from Pseudomonas putida (BFD) are thiamine diphosphate-dependent enzymes that decarboxylate 2-keto acids. Although they share a common homotetrameric structure they have relatively low sequence similarity and different substrate spectra. PDC prefers short aliphatic substrates whereas BFD favours aromatic 2-keto acids. These preferences are also reflected in their carboligation reactions. PDC catalyses the conversion of benzaldehyde and acetaldehyde to (R)-phenylacetylcarbinol and predominantly (S)-acetoin, whereas (R)-benzoin and mainly (S)-2-hydroxypropiophenone are the products of BFD catalysis. Comparison of the X-ray structures of both enzymes identified two residues in each that were likely to be involved in determining substrate specificity. Site-directed mutagenesis was used to interchange these residues in both BFD and PDC. The substrate range and kinetic parameters for the decarboxylation reaction were studied for each variant. The most successful variants, PDCI472A and BFDA460I, catalysed the decarboxylation of benzoylformate and pyruvate, respectively, although both variants now preferred the long-chain aliphatic substrates, 2-ketopentanoic and 2-ketohexanoic acid. With respect to the carboligase activity, PDCI472A proved to be a real chimera between PDC and BFD whereas BFDA460I/F464I provided the most interesting result with an almost complete reversal of the stereochemistry of its 2-hydroxypropiophenone product.
Collapse
Affiliation(s)
- Petra Siegert
- Institute of Molecular Enzyme Technology, Heinrich-Heine University of Düsseldorf, Research Centre Jülich, D-52426 Jülich, Germany
| | | | | | | | | | | | | |
Collapse
|
35
|
Aggarwal VK, Astle CJ, Iding H, Wirz B, Rogers-Evans M. Separation of pyrrolidine allylation products by diastereoselective enzymatic ester hydrolysis. Tetrahedron Lett 2005. [DOI: 10.1016/j.tetlet.2004.12.062] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Abrecht S, Harrington P, Iding H, Karpf M, Trussardi R, Wirz B, Zutter U. The Synthetic Development of the Anti-Influenza Neuraminidase Inhibitor Oseltamivir Phosphate (Tamiflu ®): A Challenge for Synthesis & Process Research. Chimia (Aarau) 2004. [DOI: 10.2533/000942904777677605] [Citation(s) in RCA: 118] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
37
|
|
38
|
Rodrı́guez Sarmiento RM, Wirz B, Iding H. Chemoenzymatic preparation of non-racemic N-Boc-pyrrolidine-3,4-dicarboxylic acid 3-ethyl esters and their 4-hydroxymethyl derivatives. ACTA ACUST UNITED AC 2003. [DOI: 10.1016/s0957-4166(03)00284-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Iding H, Wirz B, Rodrı́guez Sarmiento RM. Chemoenzymatic preparation of non-racemic N-Boc-piperidine-3,5-dicarboxylic acid 3-methyl esters and their 5-hydroxymethyl derivatives. ACTA ACUST UNITED AC 2003. [DOI: 10.1016/s0957-4166(03)00283-0] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Iding H, Dünnwald T, Greiner L, Liese A, Müller M, Siegert P, Grötzinger J, Demir AS, Pohl M. Benzoylformate decarboxylase from Pseudomonas putida as stable catalyst for the synthesis of chiral 2-hydroxy ketones. Chemistry 2000; 6:1483-95. [PMID: 10840971 DOI: 10.1002/(sici)1521-3765(20000417)6:8<1483::aid-chem1483>3.0.co;2-s] [Citation(s) in RCA: 133] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The thiamin diphosphate- and Mg2+-dependent enzyme benzoylformate decarboxylase (BFD) from Pseudomonas putida was characterized with respect to its suitability to catalyze the formation of chiral 2-hydroxy ketones in a benzoin-condensation type reaction. Carboligation constitutes a side reaction of BFD, whereas the predominant physiological task of the enzyme is the non-oxidative decarboxylation of benzoylformate. For this purpose the enzyme was obtained in sufficient purity from Pseudomonas putida cells in a one-step purification using anion-exchange chromatography. To facilitate the access to pure BFD for kinetical studies, stability investigations, and synthetical applications, the coding gene was cloned into a vector allowing the expression of a hexahistidine fusion protein. The recombinant enzyme shows distinct activity maxima for the decarboxylation and the carboligation beside a pronounced stability in a broad pH and temperature range. The enzyme accepts a wide range of donor aldehyde substrates which are ligated to acetaldehyde as an acceptor in mostly high optical purities. The enantioselectivity of the carboligation was found to be a function of the reaction temperature, the substitution pattern of the donor aldehyde and, most significantly, of the concentration of the donor aldehyde substrate. Our data are consistent with a mechanistical model based on the X-ray crystallographic data of BFD. Furthermore we present a simple way to increase the enantiomeric excess of (S)-2-hydroxy-1-phenyl-propanone from 90% to 95% by skillful choice of the reaction parameters. Enzymatic synthesis with BFD are performed best in a continuously operated enzyme membrane reactor. Thus, we have established a new enzyme tool comprising a vast applicability for stereoselective synthesis.
Collapse
Affiliation(s)
- H Iding
- Institut für Enzymtechnologie, Heinrich-Heine Universität Düsseldorf im Forschungszentrum Jülich, Jülich, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Abstract
The advantages of using enzymes in the synthesis of organic compounds relate to their versatility, high reaction rates, and regio- and stereospecificity and the relatively mild reaction conditions involved. Stereospecificity is especially important in the synthesis of bioactive molecules, as only one of the enantiomeric forms usually manifests bioactivity, whereas the other is often toxic. Although enzymes which catalyze asymmetric carbon-carbon bond formation are of great importance in bioorganic chemistry, only a few examples are known for thiamin diphosphate (ThDP)-dependent enzymes, whereas transformations using e.g. aldolases, lipases and lyases are well documented already. The present review surveys recent work on the application of pyruvate decarboxylase and benzoylformate decarboxylase in organic synthesis. These enzymes catalyze the synthesis of chiral alpha-hydroxy ketones which are versatile building blocks for organic and pharmaceutical chemistry. Besides the substrate spectra of both enzymes amino acid residues relevant for substrate specificity and enantioselectivity of pyruvate decarboxylase have been investigated by site-directed mutagenesis.
Collapse
Affiliation(s)
- H Iding
- Institut für Enzymtechnologie der Heinrich-Heine Universität Düsseldorf, im Forschungszentrum Jülich, D-52426 Jülich, Germany
| | | | | | | |
Collapse
|